Oncology Central

Dr Lisa Licitra discusses the current and future treatment landscape in recurrent/metastatic head and neck cancer

0

Leading medical oncologist, Dr Lisa Licitra, Italy, discusses the impact of emerging immunotherapies, including nivolumab, in second-line treatment of recurrent/metastatic head and neck cancer following standard-of-care treatment, cetuximab and platinum-based therapy (EXTREME regimen).

Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.